Business
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022
--- Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological Endpoints WALTHAM, Mass., Oct.
About this update from Innoviva, Inc.
[{"type":"text","content":"--- Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological Endpoints\nWALTHAM, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced the presentation of additional safety and efficacy data from the Company’s pivotal Phase 3 ATTACK trial. The study results will be presented at IDWeek 2022, the annual meeting of the Infectious Disease Society of America held October 19-23, 2022 in Washington, D.C. \"The data we are presenting at IDWeek 2022 reinforce the positive safety and efficacy findings we previously described from our topline data analysis,” said David Altarac, MD, Chief Medical Officer of Entasis. “These data underscore the potential impact of SUL-DUR, if approved, as a treatment option for patients with drug-resistant Acinetobacter infections, where no current standard of care exists.\" On Thursday, October 20 there will be two oral presentations and three poster presentations followed by an oral presentation Saturday, October 22nd. Oral Presentations An oral presentation entitled Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections will be presented October 20 1:45-3pm ET by David Altarac, MD Chief Medical Officer of Entasis. Results of the study showed non-inferiority in 28-day all-cause mortality and overall trends favoring SUL-DUR, such as higher clinical cure rate at Test of Cure and greater microbiologic favorable response at Test of Cure. The study showed that treatment with SUL-DUR demonstrated lower mortality, higher clinical cure rates, and greater microbiologically favorable outcomes than colistin in patients with carbapenem-resistant ABC infections. Concordance between clinical and microbiological outcomes was observed. The second oral presentation entitled Efficacy of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with extensively drug-resistant (XDR) and pan-drug resistant (PDR) Acinetobacter baumannii-calcoaceticus complex (ABC) infections, will ...